AI REPL Forecast

Price Forecast:


Bearish<->Bullish


Bullish Case: Replimune's RP1 shows promise with a 33% response rate in melanoma and ongoing pivotal trials suggest potential FDA acceleration, which could substantially boost investor confidence and stock price.


Bearish Case: High market volatility and skepticism surrounding delayed trial approvals or negative feedback from meetings could lead to significant price declines, particularly given REPL's recent mean-reverting behavior.


Potential Outcomes:

1. Accelerated approval success (30%).

2. Confirmatory trial delays (20%).

3. Negative pre-BLA feedback (15%).

4. Market volatility from unforeseen data/events (35%).


Trading Oracle: Sign Up to access trading oracle trade ideas.


September 20, 2024


Replimune Forecast

REPL      Replimune
















Become a more profitable investor with AI optimized trading strategies






×

Chat with REPL


 Ask any question about REPL!